Ronald won Gewritz Award

Ronald Buijsen is this year’s recipient of the Gewirtz Award for postdoctoral researchers and Young Industrial Professionals of the Oligonucleotide Therapeutics Society (OTS). He received the award for his contributions in the field of oligonucleotide therapeutics. The award is given in honor of Professor Alan Gewirtz, one of the founders of the oligonucleotide therapy field […]

CureQ consortium kick-off meeting

On Monday 3 October, the kick-off of our CureQ consortium was held: an introduction of all those involved who will work together over the next 5 years on predicting, delaying and curing the hereditary polyglutamine brain diseases Huntington, SCA1 and SCA3 (www.cureQ.nl). Researchers and neurologists from various Dutch universities, various HBO courses, ethicists, biotechnology companies, […]

SCA7 research started

The first participant of the SCA7 study reported yesterday at our Radboudumc Expertise Center for Rare and Hereditary Movement Disorders. With this, we have officially started the research into the natural course and possible biomarkers in this disease! This is an important step towards the ultimate long-term goal: slow down, stop or prevent the disease! […]

New grant: Sargenti Research Grant

Elena Daoutsali and Ronald Buijsen from the NeuroD research group were awarded the Sargenti Research Grant, organized by the Neuroscience Research Theme. The grant was for the field of neurodegenerative diseases and made possible through a donation from the legacy of mr. Sargenti to the Leiden University Fund. Together with the group of Saskia Lesnik […]

Antisense oligonucleotides as a therapy for Dutch-type Cerebral Amyloid Angiopathy (D-CAA) – New publication

After 4 years of hard work, our paper “Antisense oligonucleotide-induced amyloid precursor protein splicing modulation as a therapeutic approach for Dutch-type cerebral amyloid angiopathy” has been published in Nucleic Acid Therapeutics (DOI: 10.1089/nat.2021.0005). In this study we explored the use of an antisense oligonucleotide (AON) as a therapeutic approach for Dutch-type cerebral amyloid angiopathy (D-CAA), a […]

Dutch Center for RNA Therapeutics

On Rare Disease day, 28th of February, last year, Willeke van Roon-Mom, along with others in the LUMC, Radboudumc and Erasmus MC started the Dutch Center for RNA Therapeutics (DCRT). After exactly 1 year, the website www.rnatherapy.nl was launched on which information can be found about DCRT and updates will be posted on things going […]

Being a student in COVID-time

I’m Abel Nijkerk, and I’m a master student Biomedical Sciences at Leiden University. Since February 2020, I’ve been conducting my internship here at the Neuro-D Lab Leiden under David Parfitt‘s supervision. One of the group’s main research lines is the development of an AON for Huntington’s Disease. The group’s been using different models to test […]

Scroll to top